Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Do Tumor-Infiltrating Lymphocytes Predict Complete Pathologic Response to Neoadjuvant Systemic Therapy in Breast Cancer Patients?

NCT05206396 is registered in ClinicalTrials.gov with Ain Shams University as lead sponsor.

NCT NCT05206396
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05206396 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Do Tumor-Infiltrating Lymphocytes Predict Complete Pathologic Response to Neoadjuvant Systemic Therapy in Breast Cancer Patients?
Lead sponsor
Ain Shams University
Phase
Observational
Overall status
Unknown status
Start date
July 24, 2022
Completion date
September 30, 2024
Enrollment
270 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer